Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

In children, 2 AS03-adjuvanted A(H1N1)pdm09 vaccine doses given 21 days apart were previously shown to induce a high humoral immune response and to have an acceptable safety profile up to 42 days following the first vaccination. Here, we analyzed the persistence data from 2 open-label studies, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Sicilia, José, Arístegui, Javier, Omeñaca, Félix, Carmona, Alfonso, Tejedor, Juan C, Merino, José M, García-Corbeira, Pilar, Walravens, Karl, Bambure, Vinod, Moris, Philippe, Caplanusi, Adrian, Gillard, Paul, Dieussaert, Ilse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635840/
https://www.ncbi.nlm.nih.gov/pubmed/26176592
http://dx.doi.org/10.1080/21645515.2015.1063754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635840/
https://www.ncbi.nlm.nih.gov/pubmed/26176592
http://dx.doi.org/10.1080/21645515.2015.1063754

Ejemplares similares